Recent research has focused on developing therapeutic antibodies that block NKG2A, aiming to enhance the immune system's ability to fight cancer. Clinical trials are underway to evaluate the efficacy and safety of these therapies. Additionally, studies are exploring the role of NKG2A in infectious diseases, providing insights into how pathogens may exploit this receptor to evade the immune response.
